Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Calcified Tissue International
Erschienen in: Calcified Tissue International 1/2004

01.01.2004

Medical Management of Hypercalcemia

verfasst von: S. H. Ralston, R. Coleman, W. D. Fraser, S. J. Gallagher, D. J. Hosking, J. S. Iqbal, E. McCloskey, D. Sampson

Erschienen in: Calcified Tissue International | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Excerpt

Hypercalcemia is a common problem in routine clinical practice. It has many causes (Table 1), but the vast majority of cases are due to one of three disorders; malignant disease, primary hyperparathyroidism and vitamin D intoxication [1]. Of these conditions, cancer-associated hypercalcemia is the one that most often requires medical antihypercalcemic therapy, since surgery remains the treatment of choice for primary hyperparathyroidism [2] and most patients with vitamin D intoxication respond satisfactorily when treatment with Vitamin D is stopped [3]. …
Literatur
1.
Fisken, RA, Heath, DA, Bold, AM 1980Hypercalcemia-a hospital survey.Quart J Med49405418PubMed
2.
Bilezikian, JP 2000Primary hyperparathyroidism. When to observe and when to operate.Endocrinol Metab Clin North Am29465478
3.
Kanis, JA, Russell, RGG 1977Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its one alpha hydroxylated derivatives.Br Med J17881PubMed
4.
Parfitt, AM 1987Bone and plasma calcium homeostasis.Bone8S1S8
5.
Stewart, AF, Horst, RL, Deftos, LJ, Cadman, EC, Lang, R, Broadus, AE 1980Biochemical evaluation of patients with cancer-associated hypercalcemia.N Engl J Med30313771383PubMed
6.
Ralston, SH, Fogelman, I, Gardner, MD, Dryburgh, FJ, Cowan, RA, Boyle, IT 1984Hypercalcemia of malignancy: evidence for a non-parathyroid humoral mediator with an effect on renal tubular calcium handling.Clin Sci66187191PubMed
7.
Ralston, SH, Fogelman, I, Gardner, MD, Boyle, IT 1984Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcemia in malignancy.Br Med J288812813
8.
Isales, C, Carcangui, ML, Stewart, AF 1987Hypercalcemia in breast cancer: a re-evaluation.Am J Med8211431147PubMed
9.
Martin, TJ, Suva, LJ 1989Parathyroid hormone-related protein in hypercalcemia of malignancy.Clin Endocrinol31631647
10.
Grill, V, Ho, P, Body, JJ, Johanson, N, Kukreja, SC, Moseley, JM, Martin, TJ 1991Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer.J Clin Endocrinol Metab7313091315
11.
Burtis, WJ, Brady, TJ, Orloff, JJ, Ersbak, JB, Warrell, RP, Olson, BR, Wu, TL, Mitnick, ME, Broadus, AE, Stewart, AF 1990Immunochemical characterisation of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of malignancy.N Engl J Med32211061112PubMed
12.
Kemp, BE, Moseley, JM, Rodda, CP,  et al. 1987Parathyroid hormone-related protein of malignancy: active synthetic fragments.Science23815681570PubMed
13.
Yates, AJ, Gutierrez, GE, Smolens, P, Travis, PS, Katz, MS, Aufdemorte, TB, Boyce, BF, Hymer, TK, Poser, JW, Mundy, GR 1988Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents.J Clin Invest81932938PubMed
14.
Rizzoli, R, Pache, JC, Didierjean, L, Burger, A, Bonjour, JP 1994A thymoma as a cause of true ectopic hyperparathyroidism.J Clin Endocrinol Metab79912915PubMed
15.
Yoshimoto, K, Yamasaki, R, Sakai, H, Tezuka, U, Takahashi, M, Iizuka, M, Sekiya, T, Saito, S 1989Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia.J Clin Endocrinol Metab68976981PubMed
16.
Skrabanek, P, McPartlin, J, Powell, D 1980Tumor hypercalcemia and ectopic hyperparathyroidism.Medicine (Baltimore)59262282
17.
Shionoiri, A, Horiuchi, T, Onouchi, T, Tsutsumi, H, Ohta, M, Hosoi, T, Ito, H, Orimo, H 2000Hypercalcemia induced with the plasma levels of parathyroid hormone-related peptide in multiple myeloma.Intern Med39810813
18.
Ratcliffe, WA, Hutchesson, AC, Bundred, NJ, Ratcliffe, JG 1992Role of assays for parathyroid hormone-related protein in investigation of hypercalcaemia [see comments].Lancet339164167CrossRefPubMed
19.
Guise, TA, Mundy, GR 1998Cancer and bone [Review].Endocrine Rev191854
20.
Han, JH, Choi, SJ, Kurihara, N, Koide, M, Oba, Y, Roodman, GD 2001Macrophage inflammatory protein-1 alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.Blood9733493353CrossRefPubMed
21.
Ralston, SH, Cowan, RA, Gardner, MD, Fraser, WD, Marshall, E, Boyle, IT 1987Comparison of intestinal calcium absorption and 1,25 dihydroxyvitamin D3 levels in malignancy-associated hypercalcemia and primary hyperparathyroidism.Clin Endocrinol26281291
22.
Fukomoto, S, Matsumoto, T, Ikeda, K,  et al. 1988Clinical evaluation of calcium metabolism in adult T-cell leukaemia/lymphoma.Arch Intern Med148921925CrossRefPubMed
23.
Breslau, NA, McGuire, JL, Zerwekh, JE, Frenkel, EP, Pak, CYC 1984Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma.Ann Intern Med10017
24.
Davies, M, Hayes, ME, Mawer, EB, Lumb, GA 1985Abnormal vitamin D metabolism in Hodgkin’s lymphoma.Lancetii11861188CrossRef
25.
Peacock, M, Robertson, WG, Nordin, BEC 1969Relation between serum and urinary calcium with particular reference to parathyroid activity.Lanceti384386CrossRef
26.
Kaplan, RA, Haussler, MR, Deftos, LJ, Bone, H, Pak, CY 1977The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria.J Clin Invest59756760PubMed
27.
Buchs, B, Rizzoli, R, Bonjour, JP 1991Evaluation of bone resorption and renal tubular reabsorption of calcium and phosphate in malignant and nonmalignant hypercalcemia.Bone124756PubMed
28.
Jansson, S, Tisell, LE, Lindstedt, G, Lundberg, PA 1991Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism [see comments].Surgery110480486PubMed
29.
Falchetti, A, Bale, AE, Amorosi, A, Bordi, C, Cicchi, P, Bandini, S, Marx, SJ, Brandi, ML 1993Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11.J Clin Endocrinol Metab76139144PubMed
30.
Adams, JS 1989Vitamin D metabolite-mediated hypercalcemia.Endocrinol Metab Clin North Am18765778
31.
Zeimer, HJ, Greenaway, TM, Slavin, J, Hards, DK, Zhou, H, Doery, JC, Hunter, AN, Duffield, A, Martin, TJ, Grill, V 1998Parathyroid-hormone-related protein in sarcoidosis.Am J Pathol1521721PubMed
32.
Mawer, EB, Hann, JT, Berry, JL,  et al. 1985Vitamin D metabolism in patients intoxicated with ergocalciferol.Clin Sci68141145
33.
Mundy, GR, Shapiro, JL, Bandelin, JG, Canalis, EM, Raisz, LG 1976Direct stimulation of bone resorption by thyroid hormones.J Clin Invest58529534PubMed
34.
Stewart, AF, Adler, M, Byers, CM,  et al. 1982Calcium homeostasis in immobilization: an example of resorptive hypercalciuria.N Engl J Med30611361140PubMed
35.
Orwoll, ES 1982The milk-alkali syndrome—current concepts.Ann Intern Med97242249
36.
Menko, FH, Bijvoet, OLM, Fronen, JLHH, Sandler, LM, Adami, S, O’Riordan, JLH, Blomen-Kukenen, W 1983Familial benign hypercalcemia.Quart J Med206120140
37.
Marx, SJ, Spiegel, AM, Brown, EM, Koehler, JO, Gardner, DG, Brennan, MF, Aurbach, GD 1978Divalent cation metabolism. Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism.Am J Med65235242PubMed
38.
Pollak, MR, Brown, EM, Chou, YH, Hebert, SC, Marx, SJ, Steinmann, B, Levi, T, Seidman, CE, Seidman, JG 1993Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.Cell7512971303PubMed
39.
Parfitt, AM 1979Equilibrium and disequilibrium hypercalcemia. New light on an old concept.Metab Bone Dis Rel Res1279293
40.
Benabe, JE, Martinez-Maldonado, M 1978Hypercalcemic nephropathy.Arch Intern Med138777779CrossRefPubMed
41.
Hosking, DJ, Cowley, A, Bucknall, CA 1981Rehydration in the treatment of severe hypercalcaemia.Quart J Med50473481PubMed
42.
Iqbal, SJ, Giles, M, Ledger, S, Nanji, N, Howl, T 1988Need for albumin adjustments of urgent total serum calcium.Lancetii14771478CrossRef
43.
Merlini, G, Fitzpatrick, LA, Siris, ES,  et al. 1984A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia.J Clin Immunol4185196PubMed
44.
Grill, V, Murray, RM, Ho, PW, Santamaria, JD, Pitt, P, Potts, C, Jerums, G, Martin, TJ 1992Circulating PTH and PTHrP levels before and after treatment of tumor-induced hypercalcemia with pamidronate disodium (APD).J Clin Endocrinol Metab7414681470PubMed
45.
Hinnie, J, Bell, E, McKillop, E, Gallacher, S 2001The prevalence of familial hypocalciuric hypercalcemia.Calcif Tissue Int68216218PubMed
46.
Ralston, SH, Boyce, BF, Cowan, RA, Gardner, MD, Dryburgh, FJ, Boyle, IT 1986Humoral hypercalcemia of malignancy: metabolic and histomorphometric studies during surgical management of the primary tumour.Quart J Med277325335
47.
Ralston, SH, Gallacher, SJ, Patel, U, Campbell, J, Boyle, IT 1990Cancer-associated hypercalcemia: morbidity and mortality.Ann Intern Med112499504PubMed
48.
Ling, PJ, A’Hern, RP, Hardy, JR 1995Analysis of survival following treatment of tumour-induced hypercalcemia with intravenous pamidronate (APD). Analysis of survival following treatment of tumour-induced hypercalcemia with intravenous pamidronate (APD).Br J Cancer72206209PubMed
49.
Harinck, HIJ, Bijvoet, OLM, Platingh, AST, Body, JJ, Elte, JWF, Sleeboom, HP, Wildiers, J, Neijt, JP 1987Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.Am J Med8211331142PubMed
50.
Heller, SR, Hosking, DJ 1986Renal handling of calcium and sodium in metastatic and non-metastatic malignancy.Br Med J292583586
51.
Hasling, C, Charles, P, Mosekilde, L 1986Etidronate disodium for treating hypercalcemia of malignancy: a double blind, placebo-controlled study.Eur J Clin Invest16433437PubMed
52.
Russell, RG, Croucher, PI, Rogers, MJ 1999Bisphosphonates: pharmacology, mechanisms of action and clinical uses.Osteoporos Int9S66S80PubMed
53.
Ralston, SH 1992Medical management of hypercalcemia [Review].Br J Clin Pharm341120
54.
Ralston, SH, Gallacher, SJ, Patel, U, Dryburgh, FJ, Fraser, WD, Cowan, RA, Boyle, IT 1989Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia.Lancetii11801182CrossRef
55.
Ringerberg, QS, Ritch, PS 1987Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients.Clin Ther917
56.
Ralston, SH 1994Pathogenesis and management of cancer-associated hypercalcemia.Cancer Surveys21179196PubMed
57.
Gucalp, R, Ritch, P, Wiernik, PH,  et al. 1992Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.J Clin Oncol10134142PubMed
58.
Plosker, GL, Goa, KL 1994Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease [Review].Drugs47945982PubMed
59.
Purohit, OP, Radstone, CR, Anthony, C, Kanis, JA, Coleman, RE 1995A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy.Br J Cancer7212891293PubMed
60.
O’Rourke, NP, McCloskey, EV, Vasikaran, S, Eyres, K, Fern, D, Kanis, JA 1993Effective treatment of maligant hypercalcemia with a single intravenous infusion of clodronate.Br J Cancer67560563PubMed
61.
Rastad, J, Benson, L, Johansson, H, Knuutila, M, Pettersson, B, Wallfelt, C, Akerstrom, G, Ljunghall, S 1987Clodronate treatment in patients with malignancy-associated hypercalcemia.Acta Med Scand221489494PubMed
62.
Adami, S, Bolzicco, GP, Rizzo, A, Salvagno, G, Bertoldo, F, Rossini, M, Suppi, R, Lo Cascio, V 1987The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy.Bone Miner2395404
63.
Body, JJ, Magritte, A, Seraj, F, Sculier, JP, Borkowski, A 1989Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.J Bone Miner Res4923928
64.
Body, JJ, Pot, M, Borkowski, A, Sculier, JP, Klastersky, J 1987Dose-response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.Am J Med82957963PubMed
65.
Body, JJ, Borkowski, A, Cleeren, A, Bijvoet, OLM 1986Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.J Clin Oncol411771183PubMed
66.
Nussbaum, SR, Younger, J, VandePol, CJ, Gagel, RF, Zubler, MA, Chapman, R, Henderson, IC, Mallette, LE 1993Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.Am J Med95297304PubMed
67.
Ralston, SH, Alzaid, AA, Gallacher, SJ, Gardner, MD, Cowan, RA, Boyle, IT 1988Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcemia.Quart J Med258825834
68.
Ralston, SH, Gardner, MD, Dryburgh, FJ, Jenkins, AS, Cowan, RA, Boyle, IT 1985Comparison of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treatment of cancer-associated hypercalcemia.Lancetii907910CrossRef
69.
Sleeboom, HP, Bijvoet, OLM, Van Oosterom, AT, Gleed, JH, O’Riordan, JLH 1983Comparison of intravenous (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate and volume repletion in tumour-induced hypercalcemia.Lancetii239243CrossRef
70.
Walls, J, Ratcliffe, WA, Howell, A, Bundred, NJ 1994Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.Br J Cancer70169172PubMed
71.
Thurlimann, B, Waldburger, R, Senn, HJ, Thiebaud, D 1992Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial [see comments].Ann Oncol3619623PubMed
72.
Wuster, C, Schoter, KH, Thiebaud, D, Manegold, C, Krahl, D, Clemens, MR, Ghielmini, M, Jaeger, P, Scharla, SH 1993Methylpentylaminopropylidene bisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia.Bone Miner227785
73.
Ralston, SH, Thiebaud, D, Herrmann, Z,  et al. 1997Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia.Br J Cancer75295300PubMed
74.
Rizzoli, R, Thiebaud, D, Bundred, N,  et al. 1999Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.J Clin Endocrinol Metab8435453550PubMed
75.
Body, JJ, Lortholary, A, Romieu, G, Vigneron, AM, Ford, J 1999A dose-finding study of zoledronate in hypercalcemic cancer patients.J Bone Miner Res1415571561
76.
Major, P, Lortholary, A, Hon, J, Abdi, E, Mills, G, Menssen, HD, Yunus, F, Bell, R, Body, J, Quebe-Fehling, E, Seaman, J 2001Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.J Clin Oncol19558567PubMed
77.
Ralston, SH, Alzaid, AA, Gardner, MD, Boyle, IT 1986Treatment of cancer-associated hypercalcemia with combined aminohydroxypropylidene diphosphonate and calcitonin.Br Med J29215491550
78.
Thiebaud, D, Jaquet, AF, Burckhardt, P 1990Fast and effective treatment of malignant hypercalcemia: combination of suppositories of calcitonin and a single infusion of 3-amino-1-hydroxypropylidene-1-bisphosphonate.Arch Intern Med15021252128CrossRefPubMed
79.
Perlia, CP, Gubisch, NJH, Wolter, J, Edelberg, D, Dederick, DD, Taylor, SG 1970Mithramycin treatment of hypercalcemia.Cancer25389394PubMed
80.
Mundy, GR, Wilkinson, R, Heath, DA 1983Comparative study of the available medical therapy for hypercalcemia of malignancy.Am J Med74421432PubMed
81.
Fulmer, DH, Dimich, AB, Rothschild, EO, Myers, WPL 1972Treatment of hypercalcemia: comparison of intravenously administered phosphate, sulphate and hydrocortisone.Arch Intern Med129923930CrossRefPubMed
82.
Breuer, RI, Le Bauer, J 1967Caution in the use of phosphates in the treatment of severe hypercalcemia.J Clin Endocrinol Metab27695698PubMed
83.
Deftos, LJ, Neer, R 1974Medical management of the hypercalcemia of malignancy.Annu Rev Med25323331CrossRefPubMed
84.
Warrell Jr, RP, Murphy, WK, Schulman, P, O’Dwyer, PJ, Heller, G 1991A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia.J Clin Oncol914671475PubMed
85.
Miach, PJ, Dawborn, JK, Martin, TJ,  et al. 1975Management of the hypercalcemia of malignancy by peritoneal dialyssi.Med J Aust1782784PubMed
86.
Selby, PL, Davies, M, Marks, JS, Mawer, EB 1995Vitamin D intoxication causes hypercalcemia by increased bone resorption which responds to pamidronate.Clin Endocrinol43531536
87.
Williams, CJ, Smith, RA, Ball, RJ, Wilkinson, H 1997Hypercalcaemia in osteogenesis imperfecta treated with pamidronate [see comments].Arch Dis Child76169170PubMed
88.
Yates, AJP, Jones, TH, Mundy, KI, Hague, RV, Brown, CB, Guilland-Cumming, D, Kanis, JA 1984Immobilisation hypercalcemia in adults and treatment with clodronate.Br Med J28911111112
89.
Gallacher, SJ, Ralston, SH, Dryburgh, FJ, Logue, FC, Allam, BF, Boyce, BF, Boyle, IT 1990Immobilisation-related hypercalcemia—a possible novel mechanism and response to pamidronate.Postgrad Med J66918922PubMed
90.
McIntyre, HD, Cameron, DP, Urquhart, SM, Davies, WE 1989Immobilization hypercalcemia responding to intravenous pamidronate therapy.Postgrad Med J65244246PubMed
91.
Kedlaya, D, Brandstater, ME, Lee, JK 1998Immobilization hypercalcemia in incomplete paraplegia: successful treatment with pamidronate.Arch Phys Med Rehab79222225
92.
Gibbs, CJ, Peacock, M 1986Hypercalcemia due to sarcoidosis corrects with bisphosphonate treatment.Postgrad Med J62937938PubMed
93.
Adams, JS 1999Hypercalcemia due to granuloma forming disorders.Favus, MJ eds. Primer on the metabolic bone diseases and disorders of mineral metabolism.KluwerPhiladelphia212214
94.
Adams, JS, Diz, MM, Sharma, OP 1989Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy.Ann Intern Med111437438
95.
Adams, JS, Sharma, OP, Diz, MM, Endres, DB 1990Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia.J Clin Endocrinol Metab7010901095PubMed
96.
Silverberg, SJ, Shane, E, Jacobs, TP, Siris, E, Bilezikian, JP 1999A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.N Engl J Med34112491255CrossRefPubMed
97.
Reasner, CA, Stone, MD, Hosking, DJ, Ballah, A, Mundy, GR 1993Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.J Clin Endocrinol Metab7710671071PubMed
98.
Evans, RA 1987Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism.Aust NZ J Med175859
99.
Hamdy, NAT, Gray, RES, McCloskey, E, Galloway, J, Rattenbury, JM, Brown, CB, Kanis, JA 1987Clodronate in the medical management of hyperparathyroidism.Bone8s69s77PubMed
100.
Shane, E, Baquiran, DC, Bilezikian, JP 1981Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism.Ann Intern Med952327
101.
van Breukelen, FJM, Bijvoet, OLM, Frijlink, WB, Sleeboom, HP, Mulder, H, Van Oosterom, AT 1982Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.Calcif Tissue Int34321327PubMed
102.
Silverberg, SJ, Bilezikian, JP, Bone, HG, Talpos, GB, Horwitz, MJ, Stewart, AF 1999Therapeutic controversies in primary hyperparathyroidism.J Clin Endocrinol Metab8422752285PubMed
103.
Stewart, AF 1999Miscellaneous causes of hypercalcemia.Favus, MJ eds. Primer on the metabolic bone diseases and disorders of mineral metabolism.KluwerPhiladelphia215219
Metadaten
Titel
Medical Management of Hypercalcemia
verfasst von
S. H. Ralston
R. Coleman
W. D. Fraser
S. J. Gallagher
D. J. Hosking
J. S. Iqbal
E. McCloskey
D. Sampson
Publikationsdatum
01.01.2004
Erschienen in
Calcified Tissue International / Ausgabe 1/2004
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-001-1135-6

Weitere Artikel der Ausgabe 1/2004

Calcified Tissue International 1/2004 Zur Ausgabe

OriginalPaper

Association Between a Polymorphism Affecting an AP1 Binding Site in the Promoter of the TCIRG1 Gene and Bone Mass in Women

OriginalPaper

Does Quantitative Ultrasound of Bone Reflect More Bone Mineral Density Than Bone Microarchitecture?

OriginalPaper

Effects of 24 Months of Growth Hormone (GH) Treatment on Serum Carboxylated and Undercarboxylated Osteocalcin Levels in GH-Deficient Adults

Announcements

Announcements

OriginalPaper

Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major

Erratum

Clarification of Analysis of Hydroxyapatite Surface Coverage by Amelogenin Nanospheres (DOI: 10.1007/s00223-002-1099-1)

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise